Sensorion SA (ALSEN.PA)
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
0.28+0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-13.9%
The outlook
Sensorion SA currently reads as neutral based on strong buy — 1.4 avg of 4 analysts, below its 50- & 200-day averages, 11% of the way from its 52-week low to high, avg target +327% vs current price. This is a snapshot of current market data, not a forecast.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 4 analysts
Price trendBelow its 50- & 200-day averages
52-week range11% of the way from its 52-week low to high
Price targetAvg target +327% vs current price
Analyst price target
~12-month · 4 analysts1.21average target+326.9% vs now
Now 0.28
Low 1.00High 1.75
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$146.3M
52-wk high
0.81
52-wk low
0.22
50-day avg
0.29
200-day avg
0.35
Trailing P/E
—